89 KamimotoM.MizunoS.MatsumotoK.NakamuraT
[5] One honest caveat, though: theres no direct head-to-head Phase 3 trial yet, so all of this is stitched together from separate trials
Melissa Mendoza, FDLI Enforcement Conference (December 2025)
It is the most common form of hair loss
It does not directly address T cell autoreactivity, autoantibody production, or complement-mediated tissue damage
It is a high-standard comprehensive pharmaceutical and chemical enterprise, established in July 2018, mainly engaged in: research and development, production, and sales of chemical APIs, chemical products, food additives, and feed additives, with an annual production of 1500 tons of carnitine series products in the first phase